Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2020

View Archived Issues

First-in-human study tests BI-764524 in diabetic macular ischemia

Akeso begins first-in-human study of AK-120 for atopic dermatitis

JS InnoPharm evaluates JSI-1187 for advanced solid tumors with MAPK pathway mutations

Placental attachment theory

CH-7233163: an EGFR inhibitor active against osimertinib-resistant EGFR-T790M/C797S mutations

Novel CTH-004 CAR T cells for the treatment of ovarian cancer

Machine learning, GWAS divide and conquer PCOS

TN1-006: a gene therapy-mediated cardiac reprogramming candidate with potential for MI treatment

Bayer, Deutsches Krebsforschungszentrum present new MAP4K1 inhibitors

CECSi cells show promising preclinical results for the treatment of bullous keratopathy

New gamma-secretase inhibitors identified at Roche

Lynk Pharmaceuticals patents Janus kinase inhibitors

Dual CACNA2D1/mu-opioid receptor ligands discovered at Esteve

Emerald Health Biotechnology Espana identifies monoglyceride lipase inhibitors

FDA approves IND for phase II study of antroquinonol in patients with COVID-19

Phase I study of DS-1062 expanded to include patients with TNBC

Menarini plans phase Ib/II study of MEN-1611 in metastatic colorectal cancer

FDA clears initiation of phase III trial of siltuximab for COVID-19-associated ARDS

Early positive data for BNT-162b1 vaccine candidate against SARS-CoV-2

Recruitment starts in phase II study of DUR-928 in COVID-19 with acute liver or kidney injury

European Commission approves canagliflozin label update

Promising efficacy of SJP-1602 in models of TNBC

RO-7297089 begins first-in-human study for relapsed or refractory multiple myeloma

Chinese phase I study evaluates TQB-3558 for solid tumors

European Commission approves Janssen's Ebola vaccine regimen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...